YiSheng BioPharmaand Tavotek BioTherapeutics Announce Strategic Research Alliance Evaluating Investigational Combination of YS-ON-001 and Tavo-201/203 for Cancer Use
January 6, 2020 at 7:00 AM EST
Become a global leader in innovative molecular-targeted Biologics to improve patient quality of life
We are passionate about our global organization recognized for impact in drug discovery and development. We embrace
•Talented people with motivation and collaboration skills
•Science driven personnel •Sustainability and diversity
•TavoSelect Phage Library Platform
•TBE-Targeted Biologics Engineering Platform
•TIM-Tavo Immune Modulator Platform
•MIP-Multicyclic Intracellular Peptide Platform
Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.
Tavotek has a rich pipeline of product candidates in various stages of development, focused on cancers, autoimmune conditions, and infectious diseases.
Company management and advisors are veteran pharmaceutical executives with multiple prior successes in the development of many blockbuster biologics currently in the market. Tavotek has 3 diverse R&D platform for Biologics:
· TBE – monoclonal and multispecific antibodies against unique targets;
· TIM – novel synthetic biologic design for auto-immune diseases and chronic viral infections
· MIP – unique multi-cyclic peptides with great potency targeting intra-cellular protein-protein interactions
Tavotek has a rich and diverse pipeline across multiple therapeutic areas. It has the global angle with operations in Asia and North America.
Tavotek’s development strategy includes organic growth, biopharma collaboration, and potential clinical stage asset licensing.
Copyright © 2020 Tavotek Biotherapeutics - All Rights Reserved.